| abstract |
The present invention relates to certain novel benzylamine derivatives, to processes for their preparation, to pharmaceutical formulations containing them and to their use in medical therapy, particularly in the treatment of depression. A compounds of formula (I), wherein R1 and R2 are each independently selected form the group consisting of hydrogen, C1-4 alkyl, C6-10 aryl, C2-4 alkenyl, C6-10aryl-C1-4alkyl, thiazolylphenyl-methyl, pyridinyl-methyl, and benzisoxazolyl-phenyl-methyl; R3 and R4 are each independently selected from a group consisting of hydrogen, C1-6 alkyl, C6-10 aryl, C2-6 alkyenyl, C2-6 alkynyl, C6-10aryl-C1-6alkyl, C3-6 cycloalkyl, C4-6 cycloalkenyl, C3-6cycloalkyl-C1-4alkyl, haloC1-6alkyl, haloC2-6alkenyl, cyano, and thiophenyl-methyl; R5 represents one or more ring substituents selected from hydrogen and halogen; R6 represents a single ring substituent of formula: wherein the dotted line represents an optional bond; Y is oxygen; and R7 represents one or more substituents selected from hydrogen and halogen; or a pharmaceutically acceptable salt thereof. |